The SIRCCA Trial
SIRCCA is a first line randomised trial for those with inoperable intrahepatic cholangiocarcinoma, looking at the standard treatment of Gemcitabine and Cisplatin chemotherapy, vs SIRT (selective internal radiation therapy)* preceding the Gemcitabine and Cisplatin chemotherapy.
This international trial is now open at the following UK centres:
- The Hammersmith Hospital, London – Dr Harpreet Wasan
- The Christie Hospital, Manchester – Professor Juan Valle
And will open for recruitment at the following centre soon (information as at May 2018):
- Southampton University Hospital – Dr Brian Stedman
Dr Harpreet Wasan of Hammersmith Hospital, Imperial College London, is the UK’s Principal Investigator for this study.
For further information go to:
To download the study protocol for the SIRCCA trial, click here
* SIRT (selective internal radiation therapy) can be used to treat bile duct cancers in the liver. Millions of tiny beads, or microspheres, are fed into the hepatic artery, the main blood vessel which supplies the liver. These beads block the supply of blood to the cancer and, as they contain a radioactive substance called yttrrium-90, they also work by sending out radiation which helps to kill off the cancer cells. (This treatment is also known as radioembolisation.)